Vaccines for invasive fungal infections

F1000 Medicine Reports

Volumn 3, Issue 1, 2011, Pages

  Spellberg, Brad ^a  

^a HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; FUNGUS VACCINE; VIRULENCE FACTOR;

ARTICLE; ASPERGILLUS; CANDIDA; CRYPTOCOCCUS; ENDEMIC DISEASE; FEASIBILITY STUDY; HOST RESISTANCE; HUMAN; MORBIDITY; MORTALITY; NONHUMAN; PHAGOCYTE; SYSTEMIC MYCOSIS; TH1 CELL; TH17 CELL;

EID: 79960092108     PISSN: None     EISSN: 17575931     Source Type: Journal    
DOI: 10.3410/M3-13     Document Type: Article

References (56)

1. Perlroth J, Choi B, Spellberg B: Nosocomial fungal infections: epidemiology, diagnosis, and treatment. Med Mycol 2007, 45:321-46. (Pubitemid 46839802)
2. Wilson LS, Reyes CM, Stolpman M, Speckman J, Allen K, Beney J: The direct cost and incidence of systemic fungal infections. Value Health 2002, 5:26-34. (Pubitemid 34160368)
3. Koh AY, Köhler JR, Coggshall KT, Van Rooijen N, Pier GB: Mucosal damage and neutropenia are required for Candida albicans dissemination. PLoS Pathog 2008, 4:e35. F1000 Factor 6 Evaluated by Neil Andrew Robert Gow 01 Aug 2008
4. Spellberg B: Novel insights into disseminated candidiasis: pathogenesis research and clinical experience converge. PLoS Pathog 2008, 4:e38.
5. De Sousa dos Santos S, Lopes MH, Simonsen V, Caiaffa Filho HH: Haemophilus influenzae type b immunization in adults infected with the human immunodeficiency virus. AIDS Res Hum Retroviruses 2004, 20:493-6.
6. Dockrell DH, Poland GA, Steckelberg JM, Wollan PC, Strickland SR, Pomeroy C: Immunogenicity of three Haemophilus influenzae type b protein conjugate vaccines in HIV seropositive adults and analysis of predictors of vaccine response. Vaccine 1999, 17:2779-85. (Pubitemid 29323003)
7. Levin MJ, Gershon AA, Weinberg A, Blanchard S, Nowak B, Palumbo P, Chan CY; AIDS Clinical Trials Group 265 Team: Immunization of HIV-infected children with varicella vaccine. J Pediatr 2001, 139:305-10. (Pubitemid 32721722)
8. Tedaldi EM, Baker RK, Moorman AC, Wood KC, Fuhrer J, McCabe RE, Holmberg SD; HIV Outpatient Study (HOPS) Investigators: Hepatitis A and B vaccination practices for ambulatory patients infected with HIV. Clin Infect Dis 2004, 38:1478-84. (Pubitemid 38678612)
9. Sinsalo M, Aittoniemi J, Käyhty H, Vilpo J: Haemophilus influenzae type b (Hib) antibody concentrations and vaccination responses in patients with chronic lymphocytic leukaemia: predicting factors for response. Leuk Lymphoma 2002, 43:1967-9.
10. Nordøy T, Aaberge IS, Husebekk A, Samdal HH, Steinert S, Melby H, Kolstad A: Cancer patients undergoing chemotherapy show adequate serological response to vaccinations against influenza virus and Streptococcus pneumoniae. Med Oncol 2002, 19:71-8. (Pubitemid 34625928)
11. Leung TF, Li CK, Hung EC, Chan PK, Mo CW, Wong RP, Chik KW: Immunogenicity of a two-dose regime of varicella vaccine in children with cancers. Eur J Haematol 2004, 72:353-7. (Pubitemid 38520734)
12. Klugman KP, Madhi SA, Huebner RE, Kohberger R, Mbelle N, Pierce NK; Vaccine Trialists Group: A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 2003, 349:1341-8. (Pubitemid 37186212)
13. Madhi SA, Kuwanda L, Cutland C, Klugman KP: The impact of a 9-valent pneumococcal conjugate vaccine on the public health burden of pneumonia in HIV-infected and -uninfected children. Clin Infect Dis 2005, 40:1511-8. (Pubitemid 40628641)
14. Masur H, Kaplan JE, Holmes KK; U.S. Public Health Service; Infectious Diseases Society of America: Guidelines for preventing opportunistic infections among HIV-infected persons-2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. Ann Intern Med 2002, 137:435-78.
15. Arrowood JR, Hayney MS: Immunization recommendations for adults with cancer. Ann Pharmacother 2002, 36:1219-29. (Pubitemid 34755801)
16. Pietrella D, Rachini A, Torosantucci A, Chiani P, Brown AJ, Bistoni F, Costantino P, Mosci P, d'Enfert C, Rappuoli R, Cassone A, Vecchiarelli A: A beta-glucan-conjugate vaccine and anti-betaglucan antibodies are effective against murine vaginal candidiasis as assessed by a novel in vivo imaging technique. Vaccine 2010, 28:1717-25.
17. Torosantucci A, Bromuro C, Chiani P, De Bernardis F, Berti F, Galli C, Norelli F, Bellucci C, Polonelli L, Costantino P, Rappuoli R, Cassone A: A novel glyco-conjugate vaccine against fungal pathogens. J Exp Med 2005, 202:597-606. F1000 Factor 10 Evaluated by Arturo Casadevall 06 Oct 2005, Juergen Wendland 11 Oct 2005 (Pubitemid 41258184)
18. Bromuro C, Romano M, Chiani P, Berti F, Tontini M, Proietti D, Mori E, Torosantucci A, Costantino P, Rappuoli R, Cassone A: Beta-glucan-CRM197 conjugates as candidates antifungal vaccines. Vaccine 2010, 28:2615-23.
19. Paulovicová E, Machová E, Tulinská J, Bystrický S: Cell and antibody mediated immunity induced by vaccination with novel Candida dubliniensis mannan immunogenic conjugate. Int Immunopharmacol 2007, 7:1325-33.
20. Bromuro C, La Valle R, Sandini S, Urbani F, Ausiello CM, Morelli L, Fé d'Ostiani C, Romani L, Cassone A: A 70-kilodalton recombinant heat shock protein of Candida albicans is highly immunogenic and enhances systemic murine candidiasis. Infect Immun 1998, 66:2154-62. (Pubitemid 28194115)
21. Xin H, Dziadek S, Bundle DR, Cutler JE: Synthetic glycopeptide vaccines combining beta-mannan and peptide epitopes induce protection against candidiasis. Proc Natl Acad Sci U S A 2008, 105:13526-31.
22. Luo G, Ibrahim AS, Spellberg B, Nobile CJ, Mitchell AP, Fu Y: Candida albicans Hyr1p confers resistance to neutrophil killing and is a potential vaccine target. J Infect Dis 2010, 201:1718-28. F1000 Factor 7 Evaluated by Antonio Cassone 06 Aug 2010, Neil Andrew Robert Gow 03 Sep 2010
23. Stevens DA, Clemons KV, Liu M: Developing a vaccine against aspergillosis. Med Mycol 2010, 49(Suppl 1):S170-6.
24. Spellberg B, Ibrahim AS, Lin L, Avanesian V, Fu Y, Lipke P, Otoo H, Ho T, Edwards JE Jr.: Antibody titer threshold predicts anticandidal vaccine efficacy even though the mechanism of protection is induction of cell-mediated immunity. J Infect Dis 2008, 197:957-71.
25. Spellberg B, Ibrahim AS, Lin L, Fu Y, Avanesian V, Baquir B, Edwards J Jr.: Phagocytes are crucial end-effectors of rAls3p-N vaccine-induced protection against murine disseminated Candidiasis [abstract]. Presented at 48th Annual ICAAC/IDSA 46th Annual Meeting, 25-28 October 2008; Washington, DC.
26. Spellberg BJ, Ibrahim AS, Avenissian V, Filler SG, Myers CL, Fu Y, Edwards JE Jr: The anti-Candida albicans vaccine composed of the recombinant N terminus of Als1p reduces fungal burden and improves survival in both immunocompetent and immunocompromised mice. Infect Immun 2005, 73:6191-3. (Pubitemid 41193065)
27. Spellberg BJ, Ibrahim AS, Avanesian V, Fu Y, Myers C, Phan QT, Filler SG, Yeaman MR, Edwards JE Jr.: Efficacy of the anti-Candida rAls3p-N or rAls1p-N vaccines against disseminated and mucosal candidiasis. J Infect Dis 2006, 194:256-60. (Pubitemid 44087198)
28. Lin L, Ibrahim AS, Avanesian V, Edwards JE Jr., Fu Y, Baquir B, Taub R, Spellberg B: Vaccine immunogenicity and efficacy vary considerably by diluent used for aluminum hydroxide adjuvant. Clin Vaccine Immunol 2008, 15:582-4. (Pubitemid 351967086)
29. Lin L, Ibrahim AS, Baquir B, Avanesian V, Fu Y, Spellberg B: Immunological surrogate marker of rAls3p-N vaccine-induced protection against Staphylococcus aureus. FEMS Immunol Med Microbiol 2009, 55:293-5.
30. Lin L, Ibrahim AS, Xu X, Farber JM, Avanesian V, Baquir B, Fu Y, French SW, Edwards JE Jr., Spellberg B: Th1-Th17 cells mediate protective adaptive immunity against Staphylococcus aureus and Candida albicans infection in mice. PLoS Pathog 2009, 5: e1000703.
31. Cenci E, Mencacci A, Bacci A, Bistoni F, Kurup VP, Romani L: T cell vaccination in mice with invasive pulmonary aspergillosis. J Immunol 2000, 165:381-8. (Pubitemid 30429530)
32. Ito JI, Lyons JM: Vaccination of corticosteroid immunosuppressed mice against invasive pulmonary aspergillosis. J Infect Dis 2002, 186:869-71. (Pubitemid 35013445)
33. Bozza S, Gaziano R, Lipford GB, Montagnoli C, Bacci A, Di Francesco P, Kurup VP, Wagner H, Romani L: Vaccination of mice against invasive aspergillosis with recombinant Aspergillus proteins and CpG oligodeoxynucleotides as adjuvants. Microbes Infect 2002, 4:1281-90. (Pubitemid 35356454)
34. Bozza S, Perruccio K, Montagnoli C, Gaziano R, Bellocchio S, Burchielli E, Nkwanyuo G, Pitzurra L, Velardi A, Romani L:Adendritic cell vaccine against invasive aspergillosis in allogeneic hematopoietic transplantation. Blood 2003, 102:3807-14. (Pubitemid 37409405)
35. Ito JI, Lyons JM, Hong TB, Tamae D, Liu YK, Wilczynski SP, Kalkum M: Vaccinations with recombinant variants of Aspergillus fumigatus allergen Asp f 3 protect mice against invasive aspergillosis. Infect Immun 2006, 74:5075-84. F1000 Factor 6 Evaluated by Karl Clemons 16 Mar 2007 (Pubitemid 44300425)
36. Datta K, Pirofski LA: Towards a vaccine for Cryptococcus neoformans: principles and caveats. FEMS Yeast Res 2006, 6:525-36. (Pubitemid 43725736)
37. Shoham S, Huang C, Chen JM, Golenbock DT, Levitz SM: Toll-like receptor 4 mediates intracellular signaling without TNF-alpha release in response to Cryptococcus neoformans polysaccharide capsule. J Immunol 2001, 166:4620-6. (Pubitemid 32233748)
38. Schlageter AM, Kozel TR: Opsonization of Cryptococcus neoformans by a family of isotype-switch variant antibodies specific for the capsular polysaccharide. Infect Immun 1990, 58:1914-8. (Pubitemid 20176391)
39. Mukherjee S, Lee SC, Casadevall A: Antibodies to Cryptococcus neoformans glucuronoxylomannan enhance antifungal activity of murine macrophages. Infect Immun 1995, 63:573-9.
40. Zaragoza O, Casadevall A: Antibodies produced in response to Cryptococcus neoformans pulmonary infection in mice have characteristics of nonprotective antibodies. Infect Immun 2004, 72:4271-4. (Pubitemid 38821942)
41. Rachini A, Pietrella D, Lupo P, Torosantucci A, Chiani P, Bromuro C, Proietti C, Bistoni F, Cassone A, Vecchiarelli A: An anti-betaglucan monoclonal antibody inhibits growth and capsule formation of Cryptococcus neoformans in vitro and exerts therapeutic, anticryptococcal activity in vivo. Infect Immun 2007, 75:5085-94. (Pubitemid 350033595)
42. Datta K, Lees A, Pirofski LA: Therapeutic efficacy of a conjugate vaccine containing a peptide mimotope of cryptococcal capsular polysaccharide glucuronoxylomannan. Clin Vaccine Immunol 2008, 15:1176-87.
43. Specht CA, Nong S, Dan JM, Lee CK, Levitz SM: Contribution of glycosylation to T cell responses stimulated by recombinant Cryptococcus neoformans mannoprotein. J Infect Dis 2007, 196:796-800. (Pubitemid 47293864)
44. Lam JS, Mansour MK, Specht CA, Levitz SM: A model vaccine exploiting fungal mannosylation to increase antigen immunogenicity. J Immunol 2005, 175:7496-503. (Pubitemid 41713447)
45. Luong M, Lam JS, Chen J, Levitz SM: Effects of fungal N- and O-linked mannosylation on the immunogenicity of model vaccines. Vaccine 2007, 25:4340-4. (Pubitemid 46678569)
46. Wüthrich M, Chang WL, Klein BS: Immunogenicity and protective efficacy of the WI-1 adhesin of Blastomyces dermatitidis. Infect Immun 1998, 66:5443-9. (Pubitemid 29044642)
47. Wuthrich M, Filutowicz HI, Allen HL, Deepe GS, Klein BS: V beta1+ J beta1.1+/V alpha2+ J alpha49+ CD4+ T cells mediate resistance against infection with Blastomyces dermatitidis. Infect Immun 2007, 75:193-200.
48. Wuthrich M, Filutowicz HI, Warner T, Deepe GS Jr., Klein BS: Vaccine immunity to pathogenic fungi overcomes the requirement for CD4 help in exogenous antigen presentation to CD8+ T cells: implications for vaccine development in immune-deficient hosts. J Exp Med 2003, 197:1405-16. F1000 Factor 8 Evaluated by Paula Sundstrom 16 Aug 2004 (Pubitemid 36682540)
49. Wüthrich M, Filutowicz HI, Warner T, Klein BS: Requisite elements in vaccine immunity to Blastomyces dermatitidis: plasticity uncovers vaccine potential in immune-deficient hosts. J Immunol 2002, 169:6969-76. (Pubitemid 36899284)
50. Cox RA, Magee DM: Coccidioidomycosis: host response and vaccine development. Clin Microbiol Rev 2004, 17:804-39. (Pubitemid 39372519)
51. Shubitz LF, Yu JJ, Hung CY, Kirkland TN, Peng T, Perrill R, Simons J, Xue J, Herr RA, Cole GT, Galgiani JN: Improved protection of mice against lethal respiratory infection with Coccidioides posadasii using two recombinant antigens expressed as a single protein. Vaccine 2006, 24:5904-11. (Pubitemid 43947385)
52. Tarcha EJ, Basrur V, Hung CY, Gardner MJ, Cole GT: A recombinant aspartyl protease of Coccidioides posadasii induces protection against pulmonary coccidioidomycosis in mice. Infect Immun 2006, 74:516-27. (Pubitemid 43023107)
53. Johnson SM, Lerche NW, Pappagianis D, Yee JL, Galgiani JN, Hector RF: Safety, antigenicity, and efficacy of a recombinant coccidioidomycosis vaccine in cynomolgus macaques (Macaca fascicularis). Ann N Y Acad Sci 2007, 1111:290-300. (Pubitemid 47573038)
54. Chu JH, Feudtner C, Heydon K, Walsh TJ, Zaoutis TE: Hospitalizations for endemic mycoses: a population-based national study. Clin Infect Dis 2006, 42:822-5. (Pubitemid 43363939)
55. Barnato AE, Sanders GD, Owens DK: Cost-effectiveness of a potential vaccine for Coccidioides immitis. Emerg Infect Dis 2001, 7:797-806. (Pubitemid 33121584)
56. Brömel C, Sykes JE: Epidemiology, diagnosis, and treatment of blastomycosis in dogs and cats. Clin Tech Small Anim Pract 2005, 20:233-9. (Pubitemid 41543119)